Quick Answer
Sigyn Therapeutics, Inc. reported Stockholders Equity of -$4.46 million for fiscal year 2024.
Sigyn Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | -$4.46M | -30.6% |
| 2023 | -$3.41M | -79.3% |
| 2022 | -$1.90M | -619.3% |
| 2021 | -$264.6K | -366.8% |
| 2020 | $99.2K | +10998.8% |
| 2019 | -$910.00 | +100.0% |
| 2018 | -$3.72M | -77.4% |
| 2017 | -$2.09M | -202.7% |
| 2016 | -$691.8K | -743.6% |
| 2015 | -$82.0K | -182.5% |
| 2014 | $99.4K | +305.4% |
| 2013 | $24.5K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.92M | -50.8% | -8.8% |
| June 30, 2025 | -$5.44M | -48.1% | -10.0% |
| March 31, 2025 | -$4.95M | -23.0% | -10.9% |
| December 31, 2024 | -$4.46M | -30.6% | -13.6% |
| September 30, 2024 | -$3.92M | -9.7% | -6.8% |
| June 30, 2024 | -$3.67M | -20.7% | +8.7% |
| March 31, 2024 | -$4.02M | -71.4% | -17.8% |
| December 31, 2023 | -$3.41M | -79.3% | +4.6% |
- Sigyn Therapeutics, Inc. showed a decrease of -30.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2024 period, Sigyn Therapeutics, Inc.’s stockholders equity has declined by 18274.4% (from $24.5 thousand to -$4.46 million).
- The most recent figure is from Sigyn Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: